EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial

BACKGROUND: Epidermal growth factor receptor (EGFR) has been hypothesised to modulate the effectiveness of anti-HER2 therapy. We used a standardised, quantitative immunofluorescence assay and a novel EGFR antibody to evaluate the correlation between EGFR expression and clinical outcome in the North...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Br J Cancer
Huvudupphovsmän: Cheng, H, Ballman, K, Vassilakopoulou, M, Dueck, A C, Reinholz, M M, Tenner, K, Gralow, J, Hudis, C, Davidson, N E, Fountzilas, G, McCullough, A E, Chen, B, Psyrri, A, Rimm, D L, Perez, E A
Materialtyp: Artigo
Språk:Inglês
Publicerad: Nature Publishing Group 2014
Ämnen:
Clinical Study
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4453859/
https://ncbi.nlm.nih.gov/pubmed/25117817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.442
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk